Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Change in Account Payables: 2018-2024

Historic Change in Account Payables for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to -$6.5 million.

  • Revolution Medicines' Change in Account Payables rose 801.04% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.4 million, marking a year-over-year increase of 528.70%. This contributed to the annual value of -$6.5 million for FY2024, which is 119.91% down from last year.
  • Latest data reveals that Revolution Medicines reported Change in Account Payables of -$6.5 million as of FY2024, which was down 119.91% from $32.5 million recorded in FY2023.
  • In the past 5 years, Revolution Medicines' Change in Account Payables registered a high of $32.5 million during FY2023, and its lowest value of -$6.5 million during FY2024.
  • Its 3-year average for Change in Account Payables is $11.1 million, with a median of $7.3 million in 2022.
  • Its Change in Account Payables has fluctuated over the past 5 years, first skyrocketed by 634.10% in 2021, then plummeted by 119.91% in 2024.
  • Revolution Medicines' Change in Account Payables (Yearly) stood at $305,000 in 2020, then spiked by 634.10% to $2.2 million in 2021, then surged by 225.50% to $7.3 million in 2022, then soared by 345.51% to $32.5 million in 2023, then slumped by 119.91% to -$6.5 million in 2024.